<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03685357</url>
  </required_header>
  <id_info>
    <org_study_id>AinShamsUni Afnan</org_study_id>
    <nct_id>NCT03685357</nct_id>
  </id_info>
  <brief_title>Correlation Between Idiopathic Parkinson's Disease and Diabetes Mellitus</brief_title>
  <official_title>Investigation of the Possible Correlation Between Idiopathic Parkinson's Disease and Diabetes Mellitus in Egyptian Elderly Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Al-Azhar University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Correlation between Idiopathic Parkinson's disease and diabetes mellitus in Egyptian Elderly
      Patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Record RBDSQ (&quot;Rapid eye movement Sleep&quot; Behavior Disorder Screening Questionnaire)
           total score difference between Group 1 and Group 2 .

        2. Oral glucose tolerance test will be performed and compared between Group 3 and Group 4.

        3. Association between glucose level and motor complication of L-dopa among Idiopathic
           Parkinson's patients using Unified Parkinson's Disease Rating Scale (UDPRS).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>UPDRS (Unified Parkinson's Disease Rating) Scale)</measure>
    <time_frame>Baseline</time_frame>
    <description>Association between glucose level and motor complication of L-dopa among Idiopathic , , Parkinson's patients using Unified Parkinson's Disease Rating Scale (UDPRS)., high scores mean worsen condition</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral Glucose Tolerance Test</measure>
    <time_frame>0, 0.5 hour , 1 hour, 1.5 hour , 2 hour</time_frame>
    <description>Between Idiopathic Parkinson's patients and the Control group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RBDSQ (&quot;Rapid eye movement Sleep&quot; Behavior Disorder Screening Questionnaire)</measure>
    <time_frame>Baseline</time_frame>
    <description>among Diabetic Patients, total score 13 , high scores mean worsen condition</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Observation</condition>
  <arm_group>
    <arm_group_label>Idiopathic Parkinson's</arm_group_label>
    <description>Oral glucose tolerance test
The Unified Parkinson's Disease Rating Scale (UDPRS).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetics receive sulphonylurea group</arm_group_label>
    <description>Record RBDSQ (&quot;Rapid eye movement Sleep&quot; Behavior Disorder Screening Questionnaire) total score</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetics on sulphonylurea and metformin</arm_group_label>
    <description>Record RBDSQ (&quot;Rapid eye movement Sleep&quot; Behavior Disorder Screening Questionnaire) total score</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <description>Record RBDSQ (&quot;Rapid eye movement Sleep&quot; Behavior Disorder Screening Questionnaire) total score
Oral glucose tolerance test</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Egyptian Elderly
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diabetic Patients

          2. Idiopathic Parkinsonism

        Exclusion Criteria:

          1. Secondary Parkinsonism due to stroke, trauma and encephalitis.

          2. Drug induced Parkinsonism.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Afnan Elgnainy</last_name>
    <role>Principal Investigator</role>
    <affiliation>AinShams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Afnan Elgnainy</last_name>
    <phone>01061840761</phone>
    <email>Afnan.elgnainy@pharma.asu.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>AinShams University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Afnan Elgnainy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 22, 2018</study_first_submitted>
  <study_first_submitted_qc>September 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2018</study_first_posted>
  <last_update_submitted>September 25, 2018</last_update_submitted>
  <last_update_submitted_qc>September 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Afnan Awad-Allah Elgnainy</investigator_full_name>
    <investigator_title>Master student, teaching assistant of Clinical Pharmacy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

